JPY 6,847.00
-17.00 (-0.25%)
JPY · as of 2026-08-18 · marketstack
| Size & multiples | |||
| Market Cap | JPY 11.50T | Enterprise Value | — |
| P/E (TTM) | 25.96× | PEG (trailing) | 5.15× |
| P/S | 9.14× | P/FCF | 24.85× |
| EV/EBITDA | — | EV/EBIT | — |
| EV/Sales | — | EV/FCF | — |
| FCF Yield | 4.02% | Buyback Yield | — |
| Owner Earnings Yield | — | Shareholder Yield | — |
| Cost of capital & EVAmethodology → | |||
| Beta (5y monthly) | 0.35 | Risk-free (assumed) | 4.00% |
| Equity risk premium (assumed) | 4.23% | Cost of Equity | — |
| After-tax Cost of Debt | — | WACC | — |
| ROIC | — | EVA Spread (ROIC−WACC) | — |
| EVA | — | ||
Flows latest annual · EPS TTM JPY 263.72 · revenue TTM JPY 1.26T · FCF TTM JPY 462.55B (in JPY)
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
| Metric | Today | Own median | Own range | %ile | z | Sector med. | mo · distinct |
|---|---|---|---|---|---|---|---|
| P/E | 26.03× | only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one. | |||||
| 22.1% | — | no band (16 mo · 2 distinct) | — | — | −36.9% | 16 · 2 | |
| 29.4% | — | no band (16 mo · 2 distinct) | — | — | −15.4% | 16 · 2 | |
| 34.5% | — | no band (16 mo · 2 distinct) | — | — | −21.3% | 16 · 2 | |
| 1.9% | 24.1% | 31st | −0.55σ | 5.1% | 141 · 140 | ||
| EPS Growth 3Y | 5.0% | only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one. | |||||
| −0.0% | — | no band (16 mo · 2 distinct) | — | — | 9.0% | 16 · 2 | |
| Market Cap | $72.45B | not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series. | |||||
shown for reference only — the reconstructed distribution did not clear the band gate, so no rank is quoted.
Filed earnings only.
no P/E ladder — only 2 monthly observations — under the 12-month floor for a series line. P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Loading the monthly cohort placement…
Rich vs Health Care on P/E
P/E 50th pct
Whole-sector pool — median skews small.
| Metric | This (FY) | Peer median | IQR (25–75) | %ile |
|---|---|---|---|---|
| P/E | 26.0x | 26.0x | 13.7x–39.9x | 50 ↑rich |
| P/Sales | 9.2x | 6.3x | 1.9x–19.9x | 60 ↑rich |
| FCF Yield | 4.0% | -7.2% | -32.9%–1.4% | 84 ↑strong |
| Net Margin | 34.5% | -21.3% | -329.2%–7.1% | 95 ↑strong |
| Operating Margin | 47.6% | -34.7% | -552.6%–8.0% | 99 ↑strong |
| ROE | 22.1% | -36.9% | -92.5%–4.5% | 91 ↑strong |
Reading the covered industry pool…
Held-with peers…
Peers by disclosure language…
This company has no published industry pool year: either its industry group is untagged in our universe, we hold no annual revenue for it, or its group's newest year has not cleared the filing-alignment guard yet. This is a coverage gap, not a statement about the company.